Clinical Trial Update: Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the combination of lenvatinib and pembrolizumab with hypofractionated pelvic radiation therapy for patients with pMMR rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Aaron Wolfson | Conditions: Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma | Phase 1 | Status: RECRUITING